Landmark Study Finds Statins Significantly Lower Heart Attack Risk in People Over 70
A world-first clinical trial led by Australian researchers has delivered a major breakthrough in geriatric medicine, revealing that daily use of cholesterol-lowering medication can significantly reduce the risk of heart attacks and strokes in people aged 70 and older.
For decades, the medical community has lacked definitive evidence regarding the safety and efficacy of statins for healthy, older adults who have no prior history of heart disease. While the drugs are standard treatment for younger high-risk patients—such as those with diabetes or established cardiovascular conditions—their application in the healthy elderly has remained a subject of debate.
Bridging a Critical Research Gap
“Our society is ageing, and therefore the burden of disease is increasing,” said Adjunct Professor Mark Nelson of Monash University’s School of Public Health and Preventive Medicine. He noted that because heart disease research historically focused on middle-aged populations, older adults were often excluded from clinical trials due to concerns over polypharmacy and potential drug interactions.
To address this, researchers conducted a robust decade-long randomized controlled trial involving nearly 10,000 participants over the age of 70, supported by approximately 3,400 general practitioners across Australia. Participants who were otherwise living independently and free from prior cardiovascular events were divided into two groups: one receiving a daily statin and the other a placebo.
Significant Findings
The study, published in the New England Journal of Medicine and presented at the European Society of Cardiology Congress in Germany, yielded compelling results:
- Heart Health: Statin use decreased the risk of a first major cardiovascular event—including heart attacks, strokes, and heart surgery—by 30%.
- Efficiency: In real-world terms, one major cardiac event could be prevented for every 37 older adults treated with a daily statin over a six-year period.
- Safety: The trial found no statistically significant difference in dementia rates between the treatment and placebo groups, helping to dispel lingering concerns that statins might negatively impact cognitive health.
Expert Reaction and Limitations
The medical community has lauded the trial as a vital contribution to clinical practice. Professor James Chong, a cardiologist at Sydney’s Westmead Hospital, noted that the findings could provide elderly patients with the “confidence to take long-term statins,” potentially leading to a global shift in treatment guidelines.
However, experts also urged a nuanced approach to the data. Prof. Chong pointed out that the trial’s demographic was “almost exclusively white,” suggesting that the findings may require further validation across more diverse global populations.
Furthermore, while the medication successfully reduced the incidence of cardiovascular events, the study noted that it did not necessarily improve “disability-free survival.” Professor Tom Marwick, a cardiologist at Hobart’s Royal Hospital, observed that while the drug effectively manages heart risks, it remains unable to fully mitigate the wider, multifaceted health burdens associated with the natural aging process.
Despite the high success rate, the study also highlighted a practical challenge: patient adherence. More than 15% of participants discontinued their medication during the trial, underscoring the need for ongoing, open discussions between patients and their GPs to ensure long-term treatment success.
Lead researcher Adjunct Professor Sophia Zoungas expressed optimism that the study’s findings will now prompt a revision of clinical guidelines, enabling doctors to offer more evidence-based preventative care to the elderly population.
